- Research works
- 105 ▲ 468% vs 2013–17
- Citations
- 2k 19.0 per fractional work
- Top-10% rate
- 7.3% record average 16.5%
- Open access
- 14% world 28%
Not ranked overall: Mary Ann Liebert (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Mary Ann Liebert (United States) specialise in?
Where its research is concentrated relative to its size: Biochemistry, Genetics and Molecular Biology takes 7.1× the share of its output that it takes of world research.
- Biochemistry, Genetics and Molecular BiologyField · 20.8 works7.1×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 7.1×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 7.1×
- Medicine 2.0×
- Economics, Econometrics and Finance 1.6×
- Business, Management and Accounting 1.5×
- Decision Sciences 0.9×
- Physics and Astronomy 0.7×
- Arts and Humanities 0.6×
- Engineering 0.4×
- Neuroscience 0.4×
- Computer Science 0.3×
- Psychology 0.3×
- Health Professions 0.3×
- Social Sciences 0.1×
Who are the top researchers at Mary Ann Liebert (United States)?
Ranked on the composite score, Alex Philippidis lead among researchers whose main affiliation is Mary Ann Liebert (United States).
- 1 Alex Philippidis United States · #998,694 worldwide 74 citations · 702 works
Which keywords describe research at Mary Ann Liebert (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Genome Engineering, RNA-Guided, Ethical Issues, Regulatory Challenges, Clinical Trials, Regenerative Medicine, Patient Safety and Stem Cell Regulation.
- Innovation Policy
- Glycosylation
- Biopharmaceutical Production
- Generic Drugs
- Thalassemia
- Pediatric
- Genetic Regulation
- Big Data
- Viral Vectors
- CAR T Cells
- Health Biotechnology
- Epidemiology
- Pluripotent Stem Cells
- Capacity Building
- Embryonic Stem Cells
- Entrepreneurship
- Stem Cell Regulation
- Regenerative Medicine
- Regulatory Challenges
- RNA-Guided
- Genome Engineering
- Ethical Issues
- Clinical Trials
- Patient Safety
- Innovation
- Gene Therapy
- Emerging Markets
- Induced Pluripotent Stem Cells
- Genomic Integration
- Global Collaboration
- AAV
- Chimeric Antigen Receptor
- Healthcare
- Education
- Medical Ethics
- Sickle-cell Disease
- Drug Development Costs
- Biomedical Engineering
- Drug Delivery Systems
- Hackathons
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Genome Engineering10▲ 294×1 topic
- RNA-Guided10▲ 294×1 topic
- Ethical Issues9▲ 153×2 topics
- Regulatory Challenges9▲ 185×2 topics
- Clinical Trials9▲ 24×3 topics
- Regenerative Medicine9▲ 64×2 topics
- Patient Safety8▲ 105×1 topic
- Stem Cell Regulation8▲ 678×1 topic
- Innovation4▲ 7.8×4 topics
- Entrepreneurship4▲ 18×3 topics
- Gene Therapy4▲ 34×3 topics
- Embryonic Stem Cells3▲ 140×2 topics
- Emerging Markets3▲ 88×2 topics
- Capacity Building3▲ 95×2 topics
- Induced Pluripotent Stem Cells3▲ 210×1 topic
- Pluripotent Stem Cells3▲ 106×1 topic
- Genomic Integration3▲ 84×2 topics
- Epidemiology2◆ 1.15×3 topics
- Global Collaboration2▲ 138×1 topic
- Health Biotechnology2▲ 300×1 topic
- AAV2▲ 106×1 topic
- CAR T Cells2▲ 58×1 topic
- Chimeric Antigen Receptor2▲ 58×1 topic
- Viral Vectors2▲ 106×1 topic
- Healthcare2▲ 2.9×4 topics
- Big Data2▲ 3.4×3 topics
- Education2▲ 1.77×2 topics
- Genetic Regulation2▲ 19×2 topics
- Medical Ethics2▲ 21×1 topic
- Pediatric2▲ 47×1 topic
- Sickle-cell Disease2▲ 64×1 topic
- Thalassemia2▲ 64×1 topic
- Drug Development Costs1▲ 92×1 topic
- Generic Drugs1▲ 92×1 topic
- Biomedical Engineering1▲ 12×1 topic
- Biopharmaceutical Production1▲ 44×2 topics
- Drug Delivery Systems1▲ 34×2 topics
- Glycosylation1▲ 16×2 topics
- Hackathons1▲ 49×1 topic
- Innovation Policy1▲ 18×2 topics
Which research topics does Mary Ann Liebert (United States) publish most on?
By volume in 2022–2025: CRISPR and Genetic Engineering, Biomedical Ethics and Regulation, Pluripotent Stem Cells Research and Biotechnology and Related Fields.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CRISPR and Genetic Engineering Molecular Biology 10 works
- 2 Biomedical Ethics and Regulation Physiology 8 works
- 3 Pluripotent Stem Cells Research Molecular Biology 3 works
- 4 Biotechnology and Related Fields Public Health, Environmental and Occupational Health 2 works
- 5 CAR-T cell therapy research Oncology 2 works
- 6 Virus-based gene therapy research Genetics 2 works
- 7 Hemoglobinopathies and Related Disorders Genetics 2 works
- 8 Ethics and Legal Issues in Pediatric Healthcare Pediatrics, Perinatology and Child Health 2 works
- 9 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 10 Biomedical and Engineering Education Biomedical Engineering 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Mary Ann Liebert (United States)'s research output changed?
Output in 2018–2022 was 468% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Larchmont
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.